{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T05:37:20Z","timestamp":1792647440048,"version":"4.5.0"},"reference-count":85,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T00:00:00Z","timestamp":1740441600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T00:00:00Z","timestamp":1740441600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006313","name":"Barncancerfonden","doi-asserted-by":"publisher","award":["TJ2016-0035, PR2016-0019, PR2019-0025, PR2022-0009"],"award-info":[{"award-number":["TJ2016-0035, PR2016-0019, PR2019-0025, PR2022-0009"]}],"id":[{"id":"10.13039\/501100006313","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","award":["24 0866 SIA, 23 2843 Pj"],"award-info":[{"award-number":["24 0866 SIA, 23 2843 Pj"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2017-01653"],"award-info":[{"award-number":["2017-01653"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007231","name":"Cancerf\u00f6reningen i Stockholm","doi-asserted-by":"publisher","award":["204092, 221132"],"award-info":[{"award-number":["204092, 221132"]}],"id":[{"id":"10.13039\/501100007231","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Proteome-wide profiling has revealed that targeted drugs can have complex protein interaction landscapes. However, it\u2019s a challenge to profile drug targets while systematically accounting for the dynamic protein variations that produce populations of multiple proteoforms. We address this problem by combining thermal proteome profiling (TPP) with functional proteoform group detection to refine the target landscape of ibrutinib. In addition to known targets, we implicate additional specific functional proteoform groups linking ibrutinib to mechanisms in immunomodulation and cellular processes like Golgi trafficking, endosomal trafficking, and glycosylation. Further, we identify variability in functional proteoform group profiles in a CLL cohort, linked to treatment status and ex vivo response and resistance. This\u00a0offers deeper insights into the impacts of functional proteoform groups in a clinical treatment setting and suggests complex biological effects linked to off-target engagement. These results provide a framework for interpreting clinically observed off-target processes and adverse events, highlighting the importance of functional proteoform group-level deconvolution in understanding drug interactions and their functional impacts with potential applications in precision medicine.<\/jats:p>","DOI":"10.1038\/s41467-024-54654-8","type":"journal-article","created":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T09:30:43Z","timestamp":1740475843000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Functional proteoform group deconvolution reveals a broader spectrum of ibrutinib off-targets"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7627-6690","authenticated-orcid":false,"given":"Isabelle Rose","family":"Leo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Kunold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8172-8575","authenticated-orcid":false,"given":"Anastasia","family":"Audrey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Tampere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0963-1872","authenticated-orcid":false,"given":"J\u00fcrgen","family":"Eirich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8100-9562","authenticated-orcid":false,"given":"Janne","family":"Lehti\u00f6","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3396-4709","authenticated-orcid":false,"given":"Rozbeh","family":"Jafari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,25]]},"reference":[{"key":"54654_CR1","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/nchembio.2576","volume":"14","author":"R Aebersold","year":"2018","unstructured":"Aebersold, R. et al. How many human proteoforms are there? Nat. Chem. Biol. 14, 206\u2013214 (2018).","journal-title":"Nat. Chem. Biol."},{"key":"54654_CR2","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1038\/nm.3548","volume":"20","author":"C Liu","year":"2014","unstructured":"Liu, C. et al. The UPF1 RNA surveillance gene is commonly mutated in pancreatic adenosquamous carcinoma. Nat. Med. 20, 596\u2013598 (2014).","journal-title":"Nat. Med."},{"key":"54654_CR3","doi-asserted-by":"crossref","unstructured":"Yoshida, K. et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Blood 118, 458\u2013458 (2011).","DOI":"10.1182\/blood.V118.21.458.458"},{"key":"54654_CR4","doi-asserted-by":"crossref","unstructured":"Ruggero, D. Translational control in cancer etiology. Cold Spring Harbor Perspect. Biol. 5, a012336 (2013).","DOI":"10.1101\/cshperspect.a012336"},{"key":"54654_CR5","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/nrd.2018.21","volume":"17","author":"FM Ferguson","year":"2018","unstructured":"Ferguson, F. M. & Gray, N. S. Kinase inhibitors: the road ahead. Nat. Rev. Drug Discov. 17, 353\u2013377 (2018).","journal-title":"Nat. Rev. Drug Discov."},{"key":"54654_CR6","doi-asserted-by":"crossref","unstructured":"Centore, R. C., Sandoval, G. J., Soares, L. M. M., Kadoch, C. & Chan, H. M. Mammalian SWI\/SNF chromatin remodeling complexes: emerging mechanisms and therapeutic strategies. Trends Genet. 36, 936\u2013950 (2020).","DOI":"10.1016\/j.tig.2020.07.011"},{"key":"54654_CR7","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1038\/ncb1183","volume":"6","author":"E Jacinto","year":"2004","unstructured":"Jacinto, E. et al. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat. Cell Biol. 6, 1122\u20131128 (2004).","journal-title":"Nat. Cell Biol."},{"key":"54654_CR8","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1038\/onc.2016.363","volume":"36","author":"LC Kim","year":"2017","unstructured":"Kim, L. C., Cook, R. S. & Chen, J. mTORC1 and mTORC2 in cancer and the tumor microenvironment. Oncogene 36, 2191\u20132201 (2017).","journal-title":"Oncogene"},{"key":"54654_CR9","doi-asserted-by":"publisher","first-page":"105091","DOI":"10.1016\/j.phrs.2020.105091","volume":"160","author":"JC Boulos","year":"2020","unstructured":"Boulos, J. C., Yousof Idres, M. R. & Efferth, T. Investigation of cancer drug resistance mechanisms by phosphoproteomics. Pharmacol. Res. 160, 105091 (2020).","journal-title":"Pharmacol. Res."},{"key":"54654_CR10","doi-asserted-by":"crossref","unstructured":"Kitamura, K. & Nimura, K. Regulation of RNA splicing: aberrant splicing regulation and therapeutic targets in cancer. Cells 10, (2021).","DOI":"10.3390\/cells10040923"},{"key":"54654_CR11","doi-asserted-by":"crossref","unstructured":"Cerezo, M., Robert, C., Liu, L. & Shen, S. The role of mRNA translational control in tumor immune escape and immunotherapy resistance. Cancer Res. 81, 5596\u20135604 (2021).","DOI":"10.1158\/0008-5472.CAN-21-1466"},{"key":"54654_CR12","doi-asserted-by":"crossref","unstructured":"Li, Y. et al. Prognostic alternative mRNA splicing signature in non-small cell lung cancer. Cancer Lett. 393, 40\u201351 (2017).","DOI":"10.1016\/j.canlet.2017.02.016"},{"key":"54654_CR13","doi-asserted-by":"crossref","unstructured":"Lorentzian, A., Uzozie, A. & Lange, P. F. Origins and clinical relevance of proteoforms in pediatric malignancies. Expert Rev. Proteom. 16, 185\u2013200 (2019).","DOI":"10.1080\/14789450.2019.1575206"},{"key":"54654_CR14","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1038\/s41388-022-02179-z","volume":"41","author":"JE Melnyk","year":"2022","unstructured":"Melnyk, J. E. et al. Targeting a splicing-mediated drug resistance mechanism in prostate cancer by inhibiting transcriptional regulation by PKC\u03b21. Oncogene 41, 1536\u20131549 (2022).","journal-title":"Oncogene"},{"key":"54654_CR15","doi-asserted-by":"crossref","unstructured":"Poulikakos, P. I. et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 480, 387\u2013390 (2011).","DOI":"10.1038\/nature10662"},{"key":"54654_CR16","doi-asserted-by":"crossref","unstructured":"Johnson, D. B. et al. Acquired BRAF inhibitor resistance: a multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms. Eur. J. Cancer 51, 2792\u20132799 (2015).","DOI":"10.1016\/j.ejca.2015.08.022"},{"key":"54654_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-014-0512-9","volume":"17","author":"Z Blanchard","year":"2015","unstructured":"Blanchard, Z., Paul, B. T., Craft, B. & ElShamy, W. M. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple-negative breast cancers. Breast Cancer Res. 17, 5 (2015).","journal-title":"Breast Cancer Res."},{"key":"54654_CR18","unstructured":"Klaeger, S. et al. The target landscape of clinical kinase drugs. Science 358, (2017)."},{"key":"54654_CR19","doi-asserted-by":"crossref","unstructured":"Savitski, M. M. et al. Tracking cancer drugs in living cells by thermal profiling of the proteome. Science 346, 1255784 (2014).","DOI":"10.1126\/science.1255784"},{"key":"54654_CR20","doi-asserted-by":"publisher","first-page":"1260419","DOI":"10.1126\/science.1260419","volume":"347","author":"M Uhl\u00e9n","year":"2015","unstructured":"Uhl\u00e9n, M. et al. Proteomics. Tissue-based map of the human proteome. Science 347, 1260419 (2015).","journal-title":"Science"},{"key":"54654_CR21","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/nature10575","volume":"480","author":"JC Tran","year":"2011","unstructured":"Tran, J. C. et al. Mapping intact protein isoforms in discovery mode using top-down proteomics. Nature 480, 254\u2013258 (2011).","journal-title":"Nature"},{"key":"54654_CR22","doi-asserted-by":"crossref","unstructured":"Smith, L. M. & Kelleher, N. L. Proteoforms as the next proteomics currency. Science 359, 1106\u20131107 (2018).","DOI":"10.1126\/science.aat1884"},{"key":"54654_CR23","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/nature19949","volume":"537","author":"R Aebersold","year":"2016","unstructured":"Aebersold, R. & Mann, M. Mass-spectrometric exploration of proteome structure and function. Nature 537, 347\u2013355 (2016).","journal-title":"Nature"},{"key":"54654_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-24030-x","volume":"12","author":"I Bludau","year":"2021","unstructured":"Bludau, I. et al. Systematic detection of functional proteoform groups from bottom-up proteomic datasets. Nat. Commun. 12, 3810 (2021).","journal-title":"Nat. Commun."},{"key":"54654_CR25","doi-asserted-by":"crossref","unstructured":"Bamberger, C. et al. Deducing the presence of proteins and proteoforms in quantitative proteomics. Nat. Commun. 9, 2320 (2018).","DOI":"10.1038\/s41467-018-04411-5"},{"key":"54654_CR26","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1021\/acs.jproteome.0c00602","volume":"20","author":"M Dermit","year":"2021","unstructured":"Dermit, M., Peters-Clarke, T. M., Shishkova, E. & Meyer, J. G. Peptide Correlation Analysis (PeCorA) reveals differential proteoform regulation. J. Proteome Res. 20, 1972\u20131980 (2021).","journal-title":"J. Proteome Res."},{"key":"54654_CR27","doi-asserted-by":"crossref","unstructured":"Kurzawa, N. et al. Deep thermal profiling for detection of functional proteoform groups. Nat. Chem. Biol. 19, 962\u2013971 (2023).","DOI":"10.1038\/s41589-023-01284-8"},{"key":"54654_CR28","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1126\/science.1233606","volume":"341","author":"D Martinez Molina","year":"2013","unstructured":"Martinez Molina, D. et al. Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay. Science 341, 84\u201387 (2013).","journal-title":"Science"},{"key":"54654_CR29","doi-asserted-by":"crossref","unstructured":"Kang, J., Seshadri, M., Cupp-Sutton, K. A. & Wu, S. Toward the analysis of functional proteoforms using mass spectrometry-based stability proteomics. Front. Anal. Sci. 3, 1186623 (2023).","DOI":"10.3389\/frans.2023.1186623"},{"key":"54654_CR30","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","volume":"373","author":"JA Burger","year":"2015","unstructured":"Burger, J. A. et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N. Engl. J. Med. 373, 2425\u20132437 (2015).","journal-title":"N. Engl. J. Med."},{"key":"54654_CR31","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1056\/NEJMoa1306220","volume":"369","author":"ML Wang","year":"2013","unstructured":"Wang, M. L. et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N. Engl. J. Med. 369, 507\u2013516 (2013).","journal-title":"N. Engl. J. Med."},{"key":"54654_CR32","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1056\/NEJMoa1501548","volume":"372","author":"SP Treon","year":"2015","unstructured":"Treon, S. P. et al. Ibrutinib in previously treated Waldenstr\u00f6m\u2019s macroglobulinemia. N. Engl. J. Med. 372, 1430\u20131440 (2015).","journal-title":"N. Engl. J. Med."},{"key":"54654_CR33","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1200\/JCO.2016.70.2282","volume":"35","author":"JA Woyach","year":"2017","unstructured":"Woyach, J. A. et al. BTKC481S-mediated resistance to ibrutinib in chronic lymphocytic leukemia. J. Clin. Oncol. 35, 1437\u20131443 (2017).","journal-title":"J. Clin. Oncol."},{"key":"54654_CR34","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","volume":"370","author":"JA Woyach","year":"2014","unstructured":"Woyach, J. A. et al. Resistance mechanisms for Bruton\u2019s tyrosine kinase inhibitor ibrutinib. N. Engl. J. Med. 370, 2286\u20132294 (2014).","journal-title":"N. Engl. J. Med."},{"key":"54654_CR35","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1182\/blood.2019000854","volume":"134","author":"A Quinquenel","year":"2019","unstructured":"Quinquenel, A. et al. Prevalence of BTK and PLCG2 mutations in a real-life CLL cohort still on ibrutinib after 3 years: a FILO group study. Blood 134, 641\u2013644 (2019).","journal-title":"Blood"},{"key":"54654_CR36","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1001\/jamaoncol.2014.218","volume":"1","author":"KJ Maddocks","year":"2015","unstructured":"Maddocks, K. J. et al. Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia. JAMA Oncol. 1, 80\u201387 (2015).","journal-title":"JAMA Oncol."},{"key":"54654_CR37","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1182\/blood-2016-09-693598","volume":"129","author":"JA Woyach","year":"2017","unstructured":"Woyach, J. A. How I manage ibrutinib-refractory chronic lymphocytic leukemia. Blood 129, 1270\u20131274 (2017).","journal-title":"Blood"},{"key":"54654_CR38","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1038\/nchembio.1582","volume":"10","author":"BR Lanning","year":"2014","unstructured":"Lanning, B. R. et al. A road map to evaluate the proteome-wide selectivity of covalent kinase inhibitors. Nat. Chem. Biol. 10, 760\u2013767 (2014).","journal-title":"Nat. Chem. Biol."},{"key":"54654_CR39","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1158\/1535-7163.MCT-15-0923","volume":"15","author":"J Chen","year":"2016","unstructured":"Chen, J., Kinoshita, T., Sukbuntherng, J., Chang, B. Y. & Elias, L. Ibrutinib inhibits ERBB receptor tyrosine kinases and HER2-amplified breast cancer cell growth. Mol. Cancer Ther. 15, 2835\u20132844 (2016).","journal-title":"Mol. Cancer Ther."},{"key":"54654_CR40","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1182\/blood-2017-07-793786","volume":"130","author":"D Miklos","year":"2017","unstructured":"Miklos, D. et al. Ibrutinib for chronic graft-versus-host disease after failure of prior therapy. Blood 130, 2243\u20132250 (2017).","journal-title":"Blood"},{"key":"54654_CR41","doi-asserted-by":"publisher","first-page":"e564","DOI":"10.1097\/HS9.0000000000000564","volume":"5","author":"TA Mulder","year":"2021","unstructured":"Mulder, T. A. et al. Ibrutinib has time-dependent on- and off-target effects on plasma biomarkers and immune cells in chronic lymphocytic leukemia. Hemasphere 5, e564 (2021).","journal-title":"Hemasphere"},{"key":"54654_CR42","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1161\/CIRCULATIONAHA.120.049210","volume":"142","author":"L Xiao","year":"2020","unstructured":"Xiao, L. et al. Ibrutinib-mediated atrial fibrillation attributable to inhibition of C-terminal Src kinase. Circulation 142, 2443\u20132455 (2020).","journal-title":"Circulation"},{"key":"54654_CR43","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/s41586-019-1186-3","volume":"569","author":"M Ghandi","year":"2019","unstructured":"Ghandi, M. et al. Next-generation characterization of the Cancer Cell Line Encyclopedia. Nature 569, 503\u2013508 (2019).","journal-title":"Nature"},{"key":"54654_CR44","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/nmeth.2732","volume":"11","author":"RMM Branca","year":"2014","unstructured":"Branca, R. M. M. et al. HiRIEF LC-MS enables deep proteome coverage and unbiased proteogenomics. Nat. Methods 11, 59\u201362 (2014).","journal-title":"Nat. Methods"},{"key":"54654_CR45","doi-asserted-by":"publisher","first-page":"2506","DOI":"10.1074\/mcp.TIR119.001481","volume":"18","author":"D Childs","year":"2019","unstructured":"Childs, D. et al. Nonparametric analysis of thermal proteome profiles reveals novel drug-binding proteins. Mol. Cell. Proteom. 18, 2506\u20132515 (2019).","journal-title":"Mol. Cell. Proteom."},{"key":"54654_CR46","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/s41573-022-00409-3","volume":"21","author":"F Meissner","year":"2022","unstructured":"Meissner, F., Geddes-McAlister, J., Mann, M. & Bantscheff, M. The emerging role of mass spectrometry-based proteomics in drug discovery. Nat. Rev. Drug Discov. 21, 637\u2013654 (2022).","journal-title":"Nat. Rev. Drug Discov."},{"key":"54654_CR47","doi-asserted-by":"publisher","first-page":"D539","DOI":"10.1093\/nar\/gkac1015","volume":"51","author":"G Tsitsiridis","year":"2023","unstructured":"Tsitsiridis, G. et al. CORUM: the comprehensive resource of mammalian protein complexes-2022. Nucleic Acids Res 51, D539\u2013D545 (2023).","journal-title":"Nucleic Acids Res"},{"key":"54654_CR48","doi-asserted-by":"publisher","first-page":"3823","DOI":"10.1073\/pnas.1221785110","volume":"110","author":"HJ kleine Balderhaar","year":"2013","unstructured":"kleine Balderhaar, H. J. et al. The CORVET complex promotes tethering and fusion of Rab5\/Vps21-positive membranes. Proc. Natl. Acad. Sci. 110, 3823\u20133828 (2013).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"54654_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09800-y","volume":"10","author":"G Segala","year":"2019","unstructured":"Segala, G. et al. Vps11 and Vps18 of Vps-C membrane traffic complexes are E3 ubiquitin ligases and fine-tune signalling. Nat. Commun. 10, 1833 (2019).","journal-title":"Nat. Commun."},{"key":"54654_CR50","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.1158\/2159-8290.CD-20-1144","volume":"11","author":"S Kumar","year":"2021","unstructured":"Kumar, S. et al. CARM1 inhibition enables immunotherapy of resistant tumors by dual action on tumor cells and T cells. Cancer Discov. 11, 2050\u20132071 (2021).","journal-title":"Cancer Discov."},{"key":"54654_CR51","doi-asserted-by":"publisher","first-page":"105124","DOI":"10.1016\/j.jbc.2023.105124","volume":"299","author":"M Santos","year":"2023","unstructured":"Santos, M., Hwang, J. W. & Bedford, M. T. CARM1 arginine methyltransferase as a therapeutic target for cancer. J. Biol. Chem. 299, 105124 (2023).","journal-title":"J. Biol. Chem."},{"key":"54654_CR52","doi-asserted-by":"publisher","first-page":"106432","DOI":"10.1016\/j.leukres.2020.106432","volume":"97","author":"IG Solman","year":"2020","unstructured":"Solman, I. G. et al. Ibrutinib restores immune cell numbers and function in first-line and relapsed\/refractory chronic lymphocytic leukemia. Leuk. Res. 97, 106432 (2020).","journal-title":"Leuk. Res."},{"key":"54654_CR53","doi-asserted-by":"publisher","first-page":"3052","DOI":"10.1172\/JCI89756","volume":"127","author":"M Long","year":"2017","unstructured":"Long, M. et al. Ibrutinib treatment improves T cell number and function in CLL patients. J. Clin. Investig. 127, 3052\u20133064 (2017).","journal-title":"J. Clin. Investig."},{"key":"54654_CR54","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.cels.2018.04.011","volume":"6","author":"J Pan","year":"2018","unstructured":"Pan, J. et al. Interrogation of mammalian protein complex structure, function, and membership using genome-scale fitness screens. Cell Syst. 6, 555\u2013568.e7 (2018).","journal-title":"Cell Syst."},{"key":"54654_CR55","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1016\/j.carres.2008.01.034","volume":"343","author":"RD Smith","year":"2008","unstructured":"Smith, R. D. & Lupashin, V. V. Role of the conserved oligomeric Golgi (COG) complex in protein glycosylation. Carbohydr. Res. 343, 2024\u20132031 (2008).","journal-title":"Carbohydr. Res."},{"key":"54654_CR56","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1247\/csf.18014","volume":"43","author":"M Ishii","year":"2018","unstructured":"Ishii, M., Lupashin, V. V. & Nakano, A. Detailed analysis of the interaction of yeast COG complex. Cell Struct. Funct. 43, 119\u2013127 (2018).","journal-title":"Cell Struct. Funct."},{"key":"54654_CR57","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1158\/1078-0432.CCR-18-1286","volume":"25","author":"S Drennan","year":"2019","unstructured":"Drennan, S. et al. Ibrutinib therapy releases leukemic surface igm from antigen drive in chronic lymphocytic leukemia patients. Clin. Cancer Res. 25, 2503\u20132512 (2019).","journal-title":"Clin. Cancer Res."},{"key":"54654_CR58","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.ceb.2018.08.006","volume":"56","author":"B Simonetti","year":"2019","unstructured":"Simonetti, B. & Cullen, P. J. Actin-dependent endosomal receptor recycling. Curr. Opin. Cell Biol. 56, 22\u201333 (2019).","journal-title":"Curr. Opin. Cell Biol."},{"key":"54654_CR59","doi-asserted-by":"publisher","first-page":"E5906","DOI":"10.1073\/pnas.1524532113","volume":"113","author":"CM Buckley","year":"2016","unstructured":"Buckley, C. M. et al. WASH drives early recycling from macropinosomes and phagosomes to maintain surface phagocytic receptors. Proc. Natl. Acad. Sci. USA 113, E5906\u2013E5915 (2016).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"54654_CR60","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1038\/leu.2015.316","volume":"30","author":"S-S Chen","year":"2016","unstructured":"Chen, S.-S. et al. BTK inhibition results in impaired CXCR4 chemokine receptor surface expression, signaling and function in chronic lymphocytic leukemia. Leukemia 30, 833\u2013843 (2016).","journal-title":"Leukemia"},{"key":"54654_CR61","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1182\/blood-2017-12-823393","volume":"132","author":"A Bercusson","year":"2018","unstructured":"Bercusson, A., Colley, T., Shah, A., Warris, A. & Armstrong-James, D. Ibrutinib blocks Btk-dependent NF-\u0138B and NFAT responses in human macrophages during Aspergillus fumigatus phagocytosis. Blood 132, 1985\u20131988 (2018).","journal-title":"Blood"},{"key":"54654_CR62","doi-asserted-by":"publisher","first-page":"478","DOI":"10.3324\/haematol.2019.219220","volume":"105","author":"D Blez","year":"2020","unstructured":"Blez, D. et al. Ibrutinib induces multiple functional defects in the neutrophil response against Aspergillus fumigatus. Haematologica 105, 478\u2013489 (2020).","journal-title":"Haematologica"},{"key":"54654_CR63","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-36387-8","volume":"13","author":"Y Schurr","year":"2023","unstructured":"Schurr, Y. et al. The WASH-complex subunit Strumpellin regulates integrin \u03b1IIb\u03b23 trafficking in murine platelets. Sci. Rep. 13, 9526 (2023).","journal-title":"Sci. Rep."},{"key":"54654_CR64","doi-asserted-by":"publisher","first-page":"4298","DOI":"10.1182\/bloodadvances.2019000640","volume":"3","author":"G Dobie","year":"2019","unstructured":"Dobie, G. et al. Ibrutinib, but not zanubrutinib, induces platelet receptor shedding of GPIb-IX-V complex and integrin \u03b1IIb\u03b23 in mice and humans. Blood Adv. 3, 4298\u20134311 (2019).","journal-title":"Blood Adv."},{"key":"54654_CR65","doi-asserted-by":"publisher","first-page":"3022","DOI":"10.1016\/j.cell.2021.04.011","volume":"184","author":"EL Huttlin","year":"2021","unstructured":"Huttlin, E. L. et al. Dual proteome-scale networks reveal cell-specific remodeling of the human interactome. Cell 184, 3022\u20133040.e28 (2021).","journal-title":"Cell"},{"key":"54654_CR66","doi-asserted-by":"publisher","first-page":"W199","DOI":"10.1093\/nar\/gkz401","volume":"47","author":"Y Liao","year":"2019","unstructured":"Liao, Y., Wang, J., Jaehnig, E. J. & Shi, Z. & Zhang, B. WebGestalt 2019: gene set analysis toolkit with revamped UIs and APIs. Nucleic Acids Res. 47, W199\u2013W205 (2019).","journal-title":"Nucleic Acids Res."},{"key":"54654_CR67","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1124\/molpharm.121.000331","volume":"101","author":"SA Misek","year":"2022","unstructured":"Misek, S. A. et al. Ibrutinib blocks YAP1 activation and reverses BRAF inhibitor resistance in melanoma cells. Mol. Pharmacol. 101, 1\u201312 (2022).","journal-title":"Mol. Pharmacol."},{"key":"54654_CR68","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1038\/s41594-019-0365-0","volume":"27","author":"NPD Liau","year":"2020","unstructured":"Liau, N. P. D. et al. Negative regulation of RAF kinase activity by ATP is overcome by 14-3-3-induced dimerization. Nat. Struct. Mol. Biol. 27, 134\u2013141 (2020).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"54654_CR69","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1042\/BST20200485","volume":"49","author":"FA Cook","year":"2021","unstructured":"Cook, F. A. & Cook, S. J. Inhibition of RAF dimers: it takes two to tango. Biochem. Soc. Trans. 49, 237\u2013251 (2021).","journal-title":"Biochem. Soc. Trans."},{"key":"54654_CR70","doi-asserted-by":"publisher","first-page":"503","DOI":"10.18632\/oncotarget.28434","volume":"14","author":"B Mezquita","year":"2023","unstructured":"Mezquita, B., Reyes-Farias, M. & Pons, M. Targeting the Src N-terminal regulatory element in cancer. Oncotarget 14, 503\u2013513 (2023).","journal-title":"Oncotarget"},{"key":"54654_CR71","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33385-8","volume":"13","author":"SA Herbst","year":"2022","unstructured":"Herbst, S. A. et al. Proteogenomics refines the molecular classification of chronic lymphocytic leukemia. Nat. Commun. 13, 6226 (2022).","journal-title":"Nat. Commun."},{"key":"54654_CR72","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-020-15552-x","volume":"11","author":"MJ Bywater","year":"2020","unstructured":"Bywater, M. J. et al. Reactivation of Myc transcription in the mouse heart unlocks its proliferative capacity. Nat. Commun. 11, 1\u201317 (2020).","journal-title":"Nat. Commun."},{"key":"54654_CR73","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1000090","volume":"4","author":"C-H Wu","year":"2008","unstructured":"Wu, C.-H. et al. Combined analysis of murine and human microarrays and ChIP analysis reveals genes associated with the ability of MYC to maintain tumorigenesis. PLoS Genet 4, e1000090 (2008).","journal-title":"PLoS Genet"},{"key":"54654_CR74","doi-asserted-by":"crossref","unstructured":"Sato, K. et al. Novel oncogene 5MP1 reprograms c-Myc translation initiation to drive malignant phenotypes in colorectal cancer. EBioMedicine 44, 387\u2013402 (2019).","DOI":"10.1016\/j.ebiom.2019.05.058"},{"key":"54654_CR75","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2091-3-11","volume":"3","author":"M Kleijn","year":"2002","unstructured":"Kleijn, M. & Proud, C. G. The regulation of protein synthesis and translation factors by CD3 and CD28 in human primary T lymphocytes. BMC Biochem. 3, 1\u201312 (2002).","journal-title":"BMC Biochem."},{"key":"54654_CR76","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1182\/blood-2015-07-660969","volume":"127","author":"A Yeomans","year":"2016","unstructured":"Yeomans, A. et al. Engagement of the B-cell receptor of chronic lymphocytic leukemia cells drives global and MYC-specific mRNA translation. Blood 127, 449\u2013457 (2016).","journal-title":"Blood"},{"key":"54654_CR77","doi-asserted-by":"crossref","unstructured":"Starck, S. R. et al. Leucine-tRNA initiates at CUG start codons for protein synthesis and presentation by MHC class I. Science 336, 1719\u20131723 (2012).","DOI":"10.1126\/science.1220270"},{"key":"54654_CR78","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1093\/cid\/ciy175","volume":"67","author":"T Varughese","year":"2018","unstructured":"Varughese, T. et al. Serious infections in patients receiving ibrutinib for treatment of lymphoid cancer. Clin. Infect. Dis. 67, 687\u2013692 (2018).","journal-title":"Clin. Infect. Dis."},{"key":"54654_CR79","doi-asserted-by":"publisher","first-page":"5361569","DOI":"10.1155\/2016\/5361569","volume":"2016","author":"B Gen\u00e7ler","year":"2016","unstructured":"Gen\u00e7ler, B. & G\u00f6n\u00fcl, M. CutaneoUs Side Effects of BRAF inhibitors in advanced melanoma: review of the literature. Dermatol. Res. Pract. 2016, 5361569 (2016).","journal-title":"Dermatol. Res. Pract."},{"key":"54654_CR80","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.ejca.2021.10.034","volume":"160","author":"X Sun","year":"2022","unstructured":"Sun, X., Ma, Z., Guo, Q., Zhao, Z. & Liu, L. Ibrutinib-related skin cancer: a pharmacovigilance study from the Food and Drug Administration Adverse Event Reporting System. Eur. J. Cancer 160, 277\u2013278 (2022).","journal-title":"Eur. J. Cancer"},{"key":"54654_CR81","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/s41589-023-01459-3","volume":"20","author":"M Reinecke","year":"2024","unstructured":"Reinecke, M. et al. Chemical proteomics reveals the target landscape of 1000 kinase inhibitors. Nat. Chem. Biol. 20, 577\u2013585 (2024).","journal-title":"Nat. Chem. Biol."},{"key":"54654_CR82","doi-asserted-by":"publisher","first-page":"e98800","DOI":"10.1371\/journal.pone.0098800","volume":"9","author":"AF Rudolf","year":"2014","unstructured":"Rudolf, A. F., Skovgaard, T., Knapp, S., Jensen, L. J. & Berthelsen, J. A comparison of protein kinases inhibitor screening methods using both enzymatic activity and binding affinity determination. PLoS One 9, e98800 (2014).","journal-title":"PLoS One"},{"key":"54654_CR83","doi-asserted-by":"publisher","first-page":"4027","DOI":"10.1021\/acs.jproteome.9b00500","volume":"18","author":"M Gaetani","year":"2019","unstructured":"Gaetani, M. et al. Proteome integral solubility alteration: a high-throughput proteomics assay for target deconvolution. J. Proteome Res. 18, 4027\u20134037 (2019).","journal-title":"J. Proteome Res."},{"key":"54654_CR84","doi-asserted-by":"publisher","first-page":"69760","DOI":"10.18632\/oncotarget.11951","volume":"7","author":"A Wang","year":"2016","unstructured":"Wang, A. et al. Ibrutinib targets mutant-EGFR kinase with a distinct binding conformation. Oncotarget 7, 69760\u201369769 (2016).","journal-title":"Oncotarget"},{"key":"54654_CR85","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1002\/(SICI)1097-0258(19980430)17:8<873::AID-SIM779>3.0.CO;2-I","volume":"17","author":"RG Newcombe","year":"1998","unstructured":"Newcombe, R. G. Interval estimation for the difference between independent proportions: comparison of eleven methods. Stat. Med. 17, 873\u2013890 (1998).","journal-title":"Stat. Med."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-54654-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-54654-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-54654-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T18:59:36Z","timestamp":1740509976000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-54654-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,25]]},"references-count":85,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["54654"],"URL":"https:\/\/doi.org\/10.1038\/s41467-024-54654-8","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,25]]},"assertion":[{"value":"8 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors declare that they have no competing interests. E.K. is a current employee at Evotec, with the position beginning after contributions to this work concluded.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1948"}}